NeuroSense Therapeutics (NRSN) Competitors $1.27 +0.02 (+1.60%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NRSN vs. VRCA, EPRX, SYRS, CTXR, SPRO, PRLD, ONCO, CNTB, GANX, and RPHMShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Verrica Pharmaceuticals (VRCA), Eupraxia Pharmaceuticals (EPRX), Syros Pharmaceuticals (SYRS), Citius Pharmaceuticals (CTXR), Spero Therapeutics (SPRO), Prelude Therapeutics (PRLD), Onconetix (ONCO), Connect Biopharma (CNTB), Gain Therapeutics (GANX), and Reneo Pharmaceuticals (RPHM). These companies are all part of the "pharmaceutical preparations" industry. NeuroSense Therapeutics vs. Verrica Pharmaceuticals Eupraxia Pharmaceuticals Syros Pharmaceuticals Citius Pharmaceuticals Spero Therapeutics Prelude Therapeutics Onconetix Connect Biopharma Gain Therapeutics Reneo Pharmaceuticals Verrica Pharmaceuticals (NASDAQ:VRCA) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk. Do insiders and institutionals have more ownership in VRCA or NRSN? 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate VRCA or NRSN? Verrica Pharmaceuticals presently has a consensus price target of $11.40, indicating a potential upside of 645.10%. Given Verrica Pharmaceuticals' higher possible upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67NeuroSense Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility & risk, VRCA or NRSN? Verrica Pharmaceuticals has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Does the media refer more to VRCA or NRSN? In the previous week, NeuroSense Therapeutics had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 5 mentions for NeuroSense Therapeutics and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.65 beat NeuroSense Therapeutics' score of 0.11 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in VRCA or NRSN? Verrica Pharmaceuticals received 165 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 64.98% of users gave Verrica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVerrica PharmaceuticalsOutperform Votes16764.98% Underperform Votes9035.02% NeuroSense TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Which has higher valuation and earnings, VRCA or NRSN? NeuroSense Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$5.12M12.75-$67M-$1.88-0.81NeuroSense TherapeuticsN/AN/A-$11.28M-$0.85-1.49 Is VRCA or NRSN more profitable? NeuroSense Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. NeuroSense Therapeutics' return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Verrica Pharmaceuticals-625.06% -591.84% -100.16% NeuroSense Therapeutics N/A N/A -286.31% SummaryVerrica Pharmaceuticals beats NeuroSense Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.36M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E Ratio-1.499.36112.5515.07Price / SalesN/A386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book-9.075.324.645.01Net Income-$11.28M$153.56M$119.13M$225.46M7 Day Performance-0.01%0.12%0.78%0.37%1 Month Performance4.95%15.23%5.65%3.57%1 Year Performance173.69%41.16%36.90%29.42% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics1.1793 of 5 stars$1.27+1.6%N/A+178.9%$17.36MN/A-1.4918News CoverageGap UpVRCAVerrica Pharmaceuticals4.1911 of 5 stars$1.40-12.5%$11.40+714.3%-58.1%$68.27M$5.12M-0.7440Gap UpEPRXEupraxia PharmaceuticalsN/A$2.50flatN/AN/A$68.21MN/A-3.0929News CoverageGap UpSYRSSyros Pharmaceuticals4.6714 of 5 stars$2.52+0.4%$5.00+98.4%-5.2%$67.36M$4.15M-0.59120Earnings ReportAnalyst ForecastNews CoverageGap DownCTXRCitius Pharmaceuticals2.301 of 5 stars$0.37-7.4%$4.00+973.2%-53.4%$67.34MN/A-1.5520Positive NewsSPROSpero Therapeutics4.5915 of 5 stars$1.23-4.7%$7.00+469.1%+3.5%$66.40M$105.43M3.7346News CoverageHigh Trading VolumePRLDPrelude Therapeutics2.6414 of 5 stars$1.20-9.1%$4.75+295.8%-33.3%$66.03MN/A-0.67120Upcoming EarningsNews CoverageGap UpHigh Trading VolumeONCOOnconetix1.2486 of 5 stars$2.89-2.4%N/AN/A$64.53M$1.46M0.0012News CoveragePositive NewsGap DownCNTBConnect Biopharma3.1615 of 5 stars$1.16-0.9%$8.00+589.7%-33.3%$64.10M$24.12M0.00110GANXGain Therapeutics3.7516 of 5 stars$2.50+14.7%$7.33+193.3%-17.1%$63.84M$50,000.00-1.9220Short Interest ↓RPHMReneo Pharmaceuticals2.3163 of 5 stars$1.82+5.2%$11.01+505.1%-76.8%$60.84MN/A-0.8430Gap Down Related Companies and Tools Related Companies VRCA Competitors EPRX Competitors SYRS Competitors CTXR Competitors SPRO Competitors PRLD Competitors ONCO Competitors CNTB Competitors GANX Competitors RPHM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRSN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
